Impiego 'ragionato' dei neurolettici per il controllo dei disturbi del comportamento in corso di malattia di Alzheimer

Translated title of the contribution: Neuroleptic treatment of behaviour disorders in Alzheimer's disease

Emma Riva, Alessandro Nobili, Fabio Trecate

Research output: Contribution to journalArticle

Abstract

It is estimated that about one-half of Alzheimer's patients develop psychotic and/or behavioural signs and symptoms which can cause the most distress and difficulties to families and healthcare professionals. The prevalence and the type of problem behaviours varies remarkably with the course of Alzheimer's disease, the severity of cognitive impairment, the neuropathology and biochemical changes. The prevalence varies also in relation to the setting, sample size, rating instruments for assessment, comorbidity, coexistence of different problem behaviours and pharmacological therapies. Neuroleptics are the only documented pharmacological treatment for psychosis, agitation, suspicion, delusions and hallucinations. Neuroleptics have a number of potentially severe adverse effects, that caution against their widespread use in elderly patients. High potency agents such as haloperidol are more likely to cause Parkinsonian symptoms, while low- potency agents such as thioridazine and chlorpromazine are more likely to cause sedation, confusion, delirium, postural hypotension and peripheral anticholinergic effects. The new antipsychotic agents (atypical neuroleptics) such as risperidone, clozapine and olanzapine appear to have efficacy either superior to the traditional neuroleptics or are generally comparable with fewer side-effects. These results however refer to clinical studies in patients with schizophrenia and they have not yet been tested with demented population in well controlled trials.

Translated title of the contributionNeuroleptic treatment of behaviour disorders in Alzheimer's disease
Original languageItalian
Pages (from-to)598-603
Number of pages6
JournalRecenti Progressi in Medicina
Volume89
Issue number11
Publication statusPublished - Nov 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Neuroleptic treatment of behaviour disorders in Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this